One-year real life data of our patients with moderate-severe Crohn's disease who underwent ustekinumab therapy.

Ustekinumab appears to be effective and safe in the treatment of moderate and severe CD, particularly in cases of unresponsiveness and intolerance to biological agents such as anti-TNF, and in the achievement of clinical remission.